Modified recombinant human sulphamidase

N/A

Report date: 2026/05/07 20:00:36

Base Information

Drug NameModified recombinant human sulphamidase
Drug Alias NameRecombinant-sulfamidase-Swedish-Orphan-BiovitrumSOBI-003
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionN-sulphoglucosamine sulphohydrolase stimulants
TargetsN-sulphoglucosamine sulphohydrolase
Therapy Area/IndicationsMucopolysaccharidosis III
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTurkeyGermany
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSwedish Orphan Biovitrum Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsMucopolysaccharidosis III

Other Information

ATC CodeN/A
Related LinksN/A